Initial [18F]DCFPyL PET/CT in treatment-naïve prostate cancer: correlation with post-ADT PSA outcomes and recurrence.

Autor: Li Y; Department of Nuclear Medicine, Qilu Hospital of Shandong University, No. 107, Cultural West Road, Jinan, 250012, China., Wang S; Evomics Medical Technology Co., Ltd, Shanghai, China., Zhao S; Department of Radiology, Rizhao Hospital of Traditional Chinese Medicine, No. 35 Wanghai Road, Rizhao, 276800, China., Zhao P; Department of Nuclear Medicine, Jinan Yaoying Medical Imaging Center, Jinan, 250012, China., Huang S; Department of Nuclear Medicine, Qilu Hospital of Shandong University, No. 107, Cultural West Road, Jinan, 250012, China., Li K; Department of Nuclear Medicine, Qilu Hospital of Shandong University, No. 107, Cultural West Road, Jinan, 250012, China., Han S; Evomics Medical Technology Co., Ltd, Shanghai, China., Tian C; Evomics Medical Technology Co., Ltd, Shanghai, China., Li X; Department of Nuclear Medicine, Qilu Hospital of Shandong University, No. 107, Cultural West Road, Jinan, 250012, China. lixin16@sdu.edu.cn., Shi B; Department of Urology, Qilu Hospital of Shandong University, No. 107, Cultural West Road, Jinan, 250012, China. bkang68@sdu.edu.cn., Li X; Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. xiang.li@meduniwien.ac.at.; Department of Nuclear Medicine, Beijing Chest Hospital, Beijing, China. xiang.li@meduniwien.ac.at.
Jazyk: angličtina
Zdroj: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2024 Jul; Vol. 51 (8), pp. 2458-2466. Date of Electronic Publication: 2024 Apr 02.
DOI: 10.1007/s00259-024-06684-z
Abstrakt: Purpose: Positron emission tomography (PET) with prostate-specific membrane antigen (PSMA) targeting tracers has emerged as a valuable diagnostic tool for prostate cancer (PCa), androgen deprivation therapy (ADT) stands as the cornerstone treatment for advanced PCa, yet forecasting the response to hormonal therapy poses a significant clinical hurdle.
Methods: In a prospective cohort of 86 PCa patients undergoing short-term ADT, this study evaluated the prognostic potential of [18F]DCFPyL PET/CT scans. Comprehensive data encompassing clinical profiles, baseline prostate-specific antigen (PSA) levels, and imaging metrics were assessed. We developed predictive models for assessing decreases in PSA levels (PSA50 and PSA70) based on a combination of PET-related parameters and clinical factors. Kaplan-Meier survival analysis was utilized to ascertain the prognostic value of PET-based metrics.
Results: In this study, elevated [18F]DCFPyL uptake within the primary tumor, as indicated by a SUV ≥ 6.78 (p = 0.0024), and a reduction in the tumor volume (TV) of primary PSMA-avid tumor with PSMA-TV < 41.96 cm 3 (p = 0.038), as well as an increased burden of metastatic PSMA-avid tumor, with PSMA-TV (PSMA-TV ≥ 71.39 cm 3 ) (p = 0.012) were identified in association with diminished progression-free survival (PFS). PET and clinical parameters demonstrated constrained predictive capacity for PSA50 response as indicated by an area under the curve (AUC) of 0.442.
Conclusion: Our study revealed that pretreatment [18F]DCFPyL uptake in primary or metastatic tumor sites is prognostically relevant in high-risk PCa patients undergoing ADT. Further research is needed to develop robust predictive models in this multifaceted landscape of PCa management.
(© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: